Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D01JUF
|
||||
| Former ID |
DAP000299
|
||||
| Drug Name |
Phentolamine
|
||||
| Synonyms |
Dibasin; Fentolamin; Fentolamina; Phenotolamine; Phentalamine; Phentolaminum; Regitin; Regitine; Regitipe; Regityn; Rogitine; Phentolamine mesylate [USAN]; Phentolamine methanesulfonate; C 7337; C 7337 Ciba; Fentolamina [INN-Spanish]; Phentolamine (INN); Phentolamine [INN:BAN]; Phentolamine, methyl sulfonate; Phentolaminum [INN-Latin]; Vasomax (TN); 2-((N-(m-Hydroxyphenyl)-p-toluidino)methyl)-2-imidazoline; 2-(N'-p-Tolyl-N'-m-hydroxyphenylaminomethyl)-2-imidazoline; 2-(N-(m-Hydroxyphenyl)-p-toluidinomethyl)imidazoline; 2-(m-Hydroxy-N-p-tolylanilinomethyl)-2-imidazoline; 3-[(4,5-dihydro-1H-imidazol-2-ylmethyl)(4-methylphenyl)amino]phenol; 3-[N-(4,5-dihydro-1H-imidazol-2-ylmethyl)-4-methylanilino]phenol
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Dermal necrosis [ICD10:K05] | Approved | [1], [2] | ||
| Therapeutic Class |
Antihypertensive Agents
|
||||
| Company |
Bedford Laboratories
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C17H19N3O
|
||||
| InChI |
InChI=1S/C17H19N3O/c1-13-5-7-14(8-6-13)20(12-17-18-9-10-19-17)15-3-2-4-16(21)11-15/h2-8,11,21H,9-10,12H2,1H3,(H,18,19)
|
||||
| InChIKey |
MRBDMNSDAVCSSF-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 50-60-2
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
840956, 860967, 3249474, 5136946, 7980295, 8153547, 11112200, 11335982, 11361221, 11362891, 11365453, 11368015, 11371816, 11374477, 11376177, 11462193, 11466258, 11467378, 11485936, 11490604, 11492714, 11493891, 14848762, 26751465, 26751466, 26751467, 29224810, 46506535, 47424187, 47573329, 47573330, 47720558, 47720559, 47720560, 48018848, 48094496, 48094497, 48169316, 48169317, 48416421, 49698396, 50005392, 50085867, 50100389, 50100390, 50103967, 50103968, 50737406, 53786858, 57322944
|
||||
| SuperDrug ATC ID |
C04AB01; V03AB36
|
||||
| SuperDrug CAS ID |
cas=000050602
|
||||
| Target and Pathway | |||||
| Target(s) | D(2) dopamine receptor | Target Info | Antagonist | [3] | |
| KEGG Pathway | Rap1 signaling pathway | ||||
| cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Gap junction | |||||
| Dopaminergic synapse | |||||
| Parkinson's disease | |||||
| Cocaine addiction | |||||
| Alcoholism | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Dopamine receptor mediated signaling pathway | |||||
| Nicotine pharmacodynamics pathway | |||||
| Reactome | Dopamine receptors | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | Hypothetical Network for Drug Addiction | ||||
| Monoamine GPCRs | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Genes and (Common) Pathways Underlying Drug Addiction | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| Nicotine Activity on Dopaminergic Neurons | |||||
| References | |||||
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 502). | ||||
| REF 2 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 040235. | ||||
| REF 3 | Nesfatin-1 exerts cardiovascular actions in brain: possible interaction with the central melanocortin system. Am J Physiol Regul Integr Comp Physiol. 2009 Aug;297(2):R330-6. Epub 2009 May 27. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.